TABLE 2.
Clinicopathological characteristics of LUSC patients in training and test group.
| Covariates | Type | Total | Test | Train | P value |
|---|---|---|---|---|---|
| Age | ≤65 | 189 (38.18%) | 98 (39.68%) | 91 (36.69%) | 0.6021 |
| >65 | 300 (60.61%) | 147 (59.51%) | 153 (61.69%) | ||
| unknow | 6 (1.21%) | 2 (0.81%) | 4 (1.61%) | ||
| Gender | FEMALE | 129 (26.06%) | 68 (27.53%) | 61 (24.6%) | 0.5215 |
| MALE | 366 (73.94%) | 179 (72.47%) | 187 (75.4%) | ||
| Stage | Stage I | 242 (48.89%) | 116 (46.96%) | 126 (50.81%) | 0.8386 |
| Stage II | 159 (32.12%) | 80 (32.39%) | 79 (31.85%) | ||
| Stage III | 83 (16.77%) | 44 (17.81%) | 39 (15.73%) | ||
| Stage IV | 7 (1.41%) | 4 (1.62%) | 3 (1.21%) | ||
| unknow | 4 (0.81%) | 3 (1.21%) | 1 (0.4%) | ||
| T | T1 | 114 (23.03%) | 51 (20.65%) | 63 (25.4%) | 0.288 |
| T2 | 288 (58.18%) | 142 (57.49%) | 146 (58.87%) | ||
| T3 | 70 (14.14%) | 41 (16.6%) | 29 (11.69%) | ||
| T4 | 23 (4.65%) | 13 (5.26%) | 10 (4.03%) | ||
| M | M0 | 407 (82.22%) | 202 (81.78%) | 205 (82.66%) | 0.8694 |
| M1 | 7 (1.41%) | 4 (1.62%) | 3 (1.21%) | ||
| MX | 77 (15.56%) | 40 (16.19%) | 37 (14.92%) | ||
| unknow | 4 (0.81%) | 1 (0.4%) | 3 (1.21%) | ||
| N | N0 | 316 (63.84%) | 158 (63.97%) | 158 (63.71%) | 0.5429 |
| N1 | 128 (25.86%) | 62 (25.1%) | 66 (26.61%) | ||
| N2 | 40 (8.08%) | 19 (7.69%) | 21 (8.47%) | ||
| N3 | 5 (1.01%) | 3 (1.21%) | 2 (0.81%) | ||
| NX | 6 (1.21%) | 5 (2.02%) | 1 (0.4%) |
LUSC, lung squamous cell carcinoma; T, T stage; M, M stage; N, N stage.